Patients in the induction/re‐induction stage of AML treatment are considered high‐risk for IFD, regardless of agent, and antifungal prophylaxis is recommended. When using a strong CYP3A4 inhibitor, such as posaconazole, itraconazole or voriconazole, in combination with novel targeted therapies that are major CYP3A4 substrates, such as venetoclax, dose reductions of up to 75% of the targeted agents are indicated. Here, CYP3A4 is linked to acute myeloid leukemia.